Astrazeneca To Join The Cambridge Biomedical Campus
18 June 2013
The Cambridge Biomedical Campus forms part of one of the largest biotech cluster outside the US and hosts a number of major research laboratories and hospitals including Addenbrooke's Hospital, the Rosie Hospital, Cambridgeshire and Peterborough Mental Health Trust, the University of Cambridge School of Clinical Medicine, Cancer Research UK Cambridge Research Institute and six Medical Research Council units/centres in addition to the Laboratory of Molecular Biology.
"Our vision for the Cambridge Biomedical Campus is that it will be globally important, the announcement that AstraZeneca will move their new global R&D centre and corporate headquarters onto the campus will help us achieve this goal. AstraZeneca will be joining a vibrant biomedical community which combines leading healthcare providers and world-leading research institutions to achieve global impact by translating world-class research into better treatments for patients." Said Professor Patrick Maxwell, Regius Professor of Physic at the University of Cambridge and Chief Executive of Cambridge University Health Partners.
The Campus, which brings together biomedical research, patient care and education, dates back to 1962 when Addenbrooke's Hospital and the Medical Research Council Laboratory of Molecular Biology (LMB) moved to the current site at Hills Road. Since then the campus has been at the heart of the discovery, development and delivery of world-class health services and 16 Nobel prizes are associated with the campus.
"The Cambridge Biomedical Campus faces a very exciting future with the location of leading companies such as AstraZeneca, the blend of research, academia and delivery of healthcare will be further enhanced when Papworth Hospital, the country's leading cardiothoracic hospital, joins the campus." added Professor Maxwell.